HARVARD BIOSCIENCE INC
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
HBIO$9.26+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| HARVARD BIOSCIENCE, INC. | ||
|---|---|---|
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||
| (Unaudited, in thousands, except share and per share data) | ||
| September 30, | December 31, | |
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $4,856 | $8,614 |
| Accounts receivable, net | 14,912 | 16,043 |
| Inventories | 23,491 | 20,805 |
| Other current assets | 2,718 | 2,763 |
| Total current assets | 45,977 | 48,225 |
| Property, plant and equipment, net | 5,399 | 4,787 |
| Operating lease right-of-use assets | 5,977 | 7,172 |
| Goodwill | 9,301 | 9,559 |
| Intangible assets, net | 6,180 | 7,639 |
| Other long-term assets | 2,465 | 2,689 |
| Total assets | $75,299 | $80,071 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | 7,159 | 3,652 |
| Contract liabilities | 3,097 | 3,447 |
| Other current liabilities | 15,871 | 14,861 |
| Total current liabilities | 26,127 | 21,960 |
| Long-term debt, net | 37,153 | 35,870 |
| Deferred tax liability | 311 | 317 |
| Operating lease liabilities | 5,441 | 6,882 |
| Other long-term liabilities | 1,162 | 1,308 |
| Total liabilities | 70,194 | 66,337 |
| Stockholders' equity: | ||
| Preferred stock, par value $0.01 per share, 5,000,000 shares authorized | - | - |
| * Common stock, par value $0.01 per share, 80,000,000 shares authorized: 4,573,080 shares issued and outstanding at September 30, 2026; 4,471,989 shares issued and outstanding at December 31, 2025; | 46 | 45 |
| Additional paid-in-capital | 241,183 | 240,071 |
| Accumulated deficit | (223,667) | (214,710) |
| Accumulated other comprehensive loss | (12,457) | (11,672) |
| Total stockholders' equity | 5,105 | 13,734 |
| Total liabilities and stockholders' equity | $75,299 | $80,071 |
| * | Retroactively presented to reflect 1-for-10 reverse stock split effective on March 13, 2026. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.